Mucosal CD8+ T cell responses induced by an MCMV based vaccine vector confer protection against influenza challenge.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Oduro, Jennifer D
Boehme, Julia D
Pils, Marina C
Guzmán, Carlos A
MetadataShow full item record
AbstractCytomegalovirus (CMV) is a ubiquitous β-herpesvirus that establishes life-long latent infection in a high percentage of the population worldwide. CMV induces the strongest and most durable CD8+ T cell response known in human clinical medicine. Due to its unique properties, the virus represents a promising candidate vaccine vector for the induction of persistent cellular immunity. To take advantage of this, we constructed a recombinant murine CMV (MCMV) expressing an MHC-I restricted epitope from influenza A virus (IAV) H1N1 within the immediate early 2 (ie2) gene. Only mice that were immunized intranasally (i.n.) were capable of controlling IAV infection, despite the greater potency of the intraperitoneally (i.p.) vaccination in inducing a systemic IAV-specific CD8+ T cell response. The protective capacity of the i.n. immunization was associated with its ability to induce IAV-specific tissue-resident memory CD8+ T (CD8TRM) cells in the lungs. Our data demonstrate that the protective effect exerted by the i.n. immunization was critically mediated by antigen-specific CD8+ T cells. CD8TRM cells promoted the induction of IFNγ and chemokines that facilitate the recruitment of antigen-specific CD8+ T cells to the lungs. Overall, our results showed that locally applied MCMV vectors could induce mucosal immunity at sites of entry, providing superior immune protection against respiratory infections.
CitationPLoS Pathog. 2019 Sep 16;15(9):e1008036. doi: 10.1371/journal.ppat.1008036. eCollection 2019 Sep.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection.
- Authors: Bongard N, Le-Trilling VTK, Malyshkina A, Rückborn M, Wohlgemuth K, Wensing I, Windmann S, Dittmer U, Trilling M, Bayer W
- Issue date: 2019 Sep
- The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus.
- Authors: Tan AC, Deliyannis G, Bharadwaj M, Brown LE, Zeng W, Jackson DC
- Issue date: 2013 Jan
- Memory Inflation Drives Tissue-Resident Memory CD8<sup>+</sup> T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus.
- Authors: Morabito KM, Ruckwardt TJ, Bar-Haim E, Nair D, Moin SM, Redwood AJ, Price DA, Graham BS
- Issue date: 2018
- Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
- Authors: Ninomiya A, Ogasawara K, Kajino K, Takada A, Kida H
- Issue date: 2002 Aug 19
- Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza.
- Authors: Deliyannis G, Kedzierska K, Lau YF, Zeng W, Turner SJ, Jackson DC, Brown LE
- Issue date: 2006 Mar